全文获取类型
收费全文 | 38720篇 |
免费 | 3561篇 |
国内免费 | 2294篇 |
专业分类
耳鼻咽喉 | 393篇 |
儿科学 | 643篇 |
妇产科学 | 654篇 |
基础医学 | 4759篇 |
口腔科学 | 827篇 |
临床医学 | 4834篇 |
内科学 | 6272篇 |
皮肤病学 | 441篇 |
神经病学 | 2121篇 |
特种医学 | 1413篇 |
外国民族医学 | 16篇 |
外科学 | 4204篇 |
综合类 | 5195篇 |
现状与发展 | 7篇 |
一般理论 | 16篇 |
预防医学 | 2600篇 |
眼科学 | 1164篇 |
药学 | 3768篇 |
19篇 | |
中国医学 | 1814篇 |
肿瘤学 | 3415篇 |
出版年
2024年 | 104篇 |
2023年 | 523篇 |
2022年 | 1276篇 |
2021年 | 1764篇 |
2020年 | 1343篇 |
2019年 | 1245篇 |
2018年 | 1334篇 |
2017年 | 1231篇 |
2016年 | 1189篇 |
2015年 | 1610篇 |
2014年 | 2130篇 |
2013年 | 1989篇 |
2012年 | 2901篇 |
2011年 | 3125篇 |
2010年 | 1924篇 |
2009年 | 1593篇 |
2008年 | 2185篇 |
2007年 | 2172篇 |
2006年 | 2029篇 |
2005年 | 1983篇 |
2004年 | 1481篇 |
2003年 | 1379篇 |
2002年 | 1145篇 |
2001年 | 975篇 |
2000年 | 855篇 |
1999年 | 813篇 |
1998年 | 473篇 |
1997年 | 430篇 |
1996年 | 326篇 |
1995年 | 325篇 |
1994年 | 297篇 |
1993年 | 218篇 |
1992年 | 315篇 |
1991年 | 287篇 |
1990年 | 239篇 |
1989年 | 235篇 |
1988年 | 202篇 |
1987年 | 170篇 |
1986年 | 143篇 |
1985年 | 118篇 |
1984年 | 70篇 |
1983年 | 80篇 |
1982年 | 34篇 |
1981年 | 49篇 |
1980年 | 40篇 |
1979年 | 39篇 |
1978年 | 24篇 |
1977年 | 32篇 |
1976年 | 23篇 |
1973年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
J. Ragaz M. Lippman M. Van Rijn A. Brodie Danijela Jelovac T. Nielsen S. Dedhar D. Huntsman M. Hayes S. Dunn M. Cheung G. Sledge S. Chia A. Harris C. Bajdik C. Speers J. Spinelli D. Hayes 《Breast cancer research and treatment》2003,79(2):278-278
Tumor samples are available from over 19,600 Stage I-III breast cancer patients treated according to evolving British Columbia guidelines from 1978 to 1990. A tissue mico-array (TMA) was constructed from 930 of these patients, all of whom participated in randomized or phase II studies. Outcome was defined as 20-year Breast Cancer specific Survival (BrCaSS), with events defined as Breast Ca death. Follow up was median 17.8 years (ranges 11–28). Multiple tumor markers were tested, and results correlated with 20-year BrCaSS for markers expressed versus non-expressed. No difference in BrCaSS was found for aromatase, integrin-linked kinase (ILK), IGF-1 and Topo-isomerase-2. The negative predictive value of IHC versus FISH and ACIS-IHC versus FISH was 96 and 97%, respectively. The positive predictive value of IHC versus FISH and ACIS-IHC versus FISH was 84 and 84%, respectively. All tests, with the exception of HER-2 FISH were done by IHC. Results of other markers (VEGF, ER/PgR, hypoxia markers, etc.), and an interactive multivariate analysis adjusting for conventional prognostic factors and for all above markers, are in progress.
Conclusions
1. The TMA is a technique which provides opportunity for rapid screening of multiple genetic markers.2. Expression of Her-2/Neu, uPA, Cox-2 and Cytokeratin 17/5,6 (but not of Aromatase, ILK, TOPO-II and IGF-1) is associated with inferior BrCaSS.3. HER-2 determination by ACIS-IHC provides comparable results to IHC done manually (with a potential for more uniform reporting), and both provide comparable results to Her-2 assessment by FISH. **
ACIS-IHC:IHC red by Automated Cell Image System (M.L.) 相似文献
102.
288例老年呼吸道感染患者病原菌分布特性及药敏分析 总被引:4,自引:1,他引:4
目的: 了解老年呼吸道感染患者病原菌的分布特点及药敏特性.方法: 对288例老年呼吸道感染患者痰样本(NCCLS法)进行细菌培养,K-B纸片法进行药敏测定.结果: 患者痰中共检出病原菌400株,细菌280株,其中G-杆菌147株,占36.75%, G 球菌133株,占33.25%.肺炎克雷伯菌及铜绿假单胞菌最敏感药的是头孢他啶,敏感率均为40%以上,肺炎链球菌和金黄色葡萄球菌最敏感药的是万古霉素;检出真菌120株,占30%,以白色念珠菌为主.结论: 进行病原菌跟踪监测及时的药敏试验,对及时控制老年呼吸道感染,是不可缺少的重要环节. 相似文献
103.
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients 总被引:11,自引:0,他引:11
Chan JC Ko GT Leung DH Cheung RC Cheung MY So WY Swaminathan R Nicholls MG Critchley JA Cockram CS 《Kidney international》2000,57(2):590-600
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. BACKGROUND: In hypertensive type 2 diabetic patients, treatment with angiotensin-converting enzyme (ACE) inhibitors is associated with a lower incidence of cardiovascular events than those treated with calcium channel-blocking agents. However, the long-term renal effects of ACE inhibitors in these patients remain inconclusive. In 1989, we commenced a placebo-controlled, double-blind, randomized study to examine the anti-albuminuric effects of enalapril versus nifedipine (slow release) in 102 hypertensive, type 2 diabetic patients. These patients have been followed up for a mean trial duration of 5.5 +/- 2.2 years. We examined the determinants, including the effect of ACE inhibition on clinical outcomes in these patients. METHODS: After a six-week placebo-controlled, run-in period, 52 patients were randomized double-blind to receive nifedipine (slow release) and 50 patients to receive enalapril. After the one-year analysis, which confirmed the superior anti-albuminuric effects of enalapril (-54%) over nifedipine (+11%), all patients were continued on their previously assigned treatment with informed consent. They were subdivided into normoalbuminuric (N = 43), microalbuminuric (N = 34), and macroalbuminuric (N = 25) groups based on two of three 24-hour urinary albumin excretion (UAE) measurements during the run-in period. Renal function was shown by the 24-hour UAE, creatinine clearance (CCr), and the regression coefficient of the yearly plasma creatinine reciprocal (beta-1/Cr). Clinical endpoints were defined as death, cardiovascular events, and/or renal events (need for renal replacement therapy or doubling of baseline plasma creatinine). RESULTS: In the whole group, patients treated with enalapril were more likely to revert to being normoalbuminuric (23.8 vs. 15.4%), and fewer of them developed macroalbuminuria (19.1 vs. 30.8%) compared with the nifedipine-treated patients (P < 0.05). In the microalbuminuric group, treatment with enalapril (N = 21) was associated with a 13.0% (P < 0.01) reduction in 24-hour UAE compared with a 17.3% increase in the nifedipine group (N = 13). In the macroalbuminuric patients, enalapril treatment (N = 11) was associated with stabilization compared with a decline in renal function in the nifedipine group, as shown by the beta-1/Cr (0.65 +/- 4.29 vs. -1.93 +/- 2.35 1/micromol x 10-3, P < 0.05) after adjustment for baseline values. Compared with the normoalbuminuric and microalbuminuric patients, those with macroalbuminuria had the lowest mean CCr (75.5 +/- 24.1 vs. 63.5 +/- 21.3 vs. 41.9 +/- 18.5 mL/min, P < 0.001) and the highest frequency of clinical events (4.7 vs. 5.9 vs. 52%, P < 0. 001). On multivariate analysis, beta-1/Cr (R2 = 0.195, P < 0.001) was independently associated with baseline HbA1c (beta = -0.285, P = 0.004), whereas clinical outcomes (R2 = 0.176, P < 0.001) were independently related to the mean low-density lipoprotein cholesterol (beta = 2.426, P = 0.018), high-density lipoprotein cholesterol (beta = -8.797, P = 0.03), baseline UAE (beta = 0.002, P = 0.04), and mean CCr during treatment (beta = -0.211, P = 0.006). CONCLUSION: In this prospective cohort analysis involving 102 hypertensive, type 2 diabetic patients with varying degrees of albuminuria followed up for a mean duration of five years, we observed the importance of good metabolic and blood pressure control on the progression of albuminuria and renal function. Treatment with enalapril was associated with a greater reduction in albuminuria than with nifedipine in the entire patient group, and especially in those with microalbuminuria. In the macroalbuminuric patients, the rate of deterioration in renal function was also attenuated by treatment with enalapril. 相似文献
104.
105.
106.
经上颌窦前壁钻孔行鼻窦内窥镜术30例报告 总被引:1,自引:0,他引:1
报告经上颌窦前壁钻孔行鼻窦内窥镜手术30例,疗效较好。与鼻腔、鼻窦内窥镜手术比较,该术式具有观察方便,出血少,反应轻,操作方便,并发症少,术后复发率低等优点。 相似文献
107.
普通额镜下鼻内激光泪囊鼻腔造孔术治疗慢性泪囊炎 总被引:11,自引:0,他引:11
报告在普通额镜下以YAG激光经鼻腔行泪囊鼻腔造孔术,治疗慢性泪囊炎患者37例(45眼),经3~24个月的随访观察,泪道阻塞均解除,有效率为95.6%,治愈率为88.9%。本手术具有损伤小,操作简便,快捷,术后反应轻,并发症少等优点。并对手术方法及影响疗效的因素进行了探讨。 相似文献
108.
以脉冲角加速度刺激在豚鼠记录出短潜伏期诱发反应,反应由发生于刺激开始后10ms以内的5~7个波组成,高强度刺激时反应振幅数微伏,I波潜伏期约2.5ms,不同动物及同一动物不同时间测试反应非常稳定。系列实验结果表明脉冲角加速度刺激诱发的豚鼠短潜伏期诱发反应系前庭诱发电位。 相似文献
109.
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11 总被引:5,自引:0,他引:5
Shouji Nakatsu S. Kondo Yasuko Kondo Dali Yin John W. Peterson Rami Kaakaji Tatsuo Morimura Haruhiko Kikuchi Juji Takeuchi Gene H. Barnett 《Cancer chemotherapy and pharmacology》1997,39(5):417-423
The overexpression of the multidrug resistance (mdr1) gene and its product, P-glycoprotein (P-gp), is thought to limit the successful chemotherapy of human tumors. Recent studies
demonstrate that SN-38, a metabolite of the camptothecin (CPT) derivative CPT-11, has antitumor effects on several tumors,
but the mechanisms responsible for its cytotoxicity remain unclear. We therefore determined whether SN-38 has cytotoxic effects
on MDR human glioblastoma GB-1 cells and non-MDR human glioblastoma U87-MG cells. Furthermore, we determined what role SN-38
plays in the induction of cytotoxicity in these tumor cells. In this study, we demonstrated that SN-38 had significantly stronger
antitumor effects on GB-1 and U-87MG cells than did CPT (P<0.01 and P<0.05, respectively). In addition, findings obtained using a DNA fragmentation assay, Hoechst 33258 staining, in situ end-labeling
and cell cycle analysis demonstrated that SN-38 induced apoptosis in these tumors. Our results suggest that SN-38 has a stronger
antitumor effect on malignant glioma cells regardless of MDR expression than does CPT, and therefore can be considered a new
chemotherapeutic agent potentially effective in the treatment of human primary or recurrent malignant gliomas resistant to
chemotherapy.
Received: 6 October 1995/Accepted 29 June 1996 相似文献
110.
食管异物摘取术的麻醉选择 总被引:7,自引:1,他引:7
为探讨食管异物摘取术的麻醉方法,提高手术效果,对72例食管异物患者采用强化表面麻醉法和气管内插管麻醉法进行了手术和对比观察。72例异物均取出顺利,无严重并发症发生。资料显示:两种麻醉各具优越性,前者适用于年龄较大的儿童和成人,后者适用于食管异物并呼吸困难的小儿。 相似文献